JAN 5·Investing.comMed
Ironwood Pharmaceuticals stock price target raised to $5 by Wells Fargo
Wells Fargo increased its price target for Ironwood Pharmaceuticals (NASDAQ: IRWD) to $5.00 from $3.00, maintaining an "Equal Weight" rating. This adjustment follows Ironwood's strong guidance for its drug Linzess in fiscal year 2026, projected to achieve U.S. net sales of $1.125 billion to $1.175 billion, driven by pricing tailwinds amid a strategic list price reduction. Despite the positive outlook and other recent developments including a settlement with Ferring International and a Citizens upgrade, Wells Fargo remains cautious, emphasizing the critical importance of Apra's success for the stock's future performance.